Menu
Search
|

Menu

Close
X

Seres Therapeutics Inc MCRB.OQ (NASDAQ Stock Exchange Global Select Market)

8.03 USD
-0.72 (-8.23%)
As of 1:30 AM IST
chart
Previous Close 8.75
Open 8.82
Volume 53,091
3m Avg Volume 51,386
Today’s High 8.82
Today’s Low 7.83
52 Week High 17.33
52 Week Low 6.65
Shares Outstanding (mil) 40.51
Market Capitalization (mil) 482.91
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY18
4
FY17
32
FY16
19
FY15
0
EPS (USD)
FY18
-0.687
FY17
-2.210
FY16
-3.104
FY15
-2.539
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
21.87
5.73
Price to Book (MRQ)
vs sector
5.48
5.45
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
11.21
16.72
LT Debt to Equity (MRQ)
vs sector
11.21
12.39
Return on Investment (TTM)
vs sector
-41.51
14.61
Return on Equity (TTM)
vs sector
-76.34
16.34

EXECUTIVE LEADERSHIP

Roger Pomerantz
Chairman of the Board, President, Chief Executive Officer, Since 2014
Salary: $564,500.00
Bonus: --
Eric Shaff
Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer, Since 2018
Salary: --
Bonus: --
John Aunins
Chief Technology Officer, Executive Vice President - Bioprocess and Manufacturing, Since 2012
Salary: --
Bonus: --
David Cook
Chief Scientific Officer, Executive Vice President - Research & Development, Since 2012
Salary: --
Bonus: --
Thomas DesRosier
Chief Legal Officer, Executive Vice President and Secretary, Since 2016
Salary: $243,750.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

200 Sidney St
CAMBRIDGE   MA   02139-4218

Phone: +1617.9459626

Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens.

SPONSORED STORIES